Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Brenner

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|July 25, 2000
15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cellsI Shureiqi, D Chen, J J Lee, et al.
Journal of the American Geriatrics Society|July 1, 1994
Causes of death associated with Alzheimer disease: variation by level of cognitive impairment before deathW A Kukull, D E Brenner, C E Speck, et al.
Annals of Surgery|January 1, 1989
A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniquesK I Bland, A K Kimura, D E Brenner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1986
Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trialL B Anthony, M G Krozely, N J Woodward, et al.
Journal of Biological Response Modifiers|October 1, 1990
Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancerP J Creaven, J W Cowens, D E Brenner, et al.
Cancer Treatment Reports|April 1, 1985
Phase II study of spirogermanium in patients with advanced carcinoma of the cervixD E Brenner, N B Rosenshein, M Dillon, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1993
Mutual kinetic interaction between 5-fluorouracil and bromodeoxyuridine or iododeoxyuridine in dogsD E Smith, D E Brenner, C A Knutsen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 16, 2001
Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancerK Krishnan, M T Ruffin, D Normolle, et al.
Cancer Treatment Reports|February 1, 1983
Phase II evaluation of spirogermanium in advanced ovarian carcinomaD E Brenner, H W Jones, N B Rosenshein, et al.
Journal of the National Cancer Institute|August 6, 1997
Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin doseM T Ruffin, K Krishnan, C L Rock, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|July 25, 2000
15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cellsI Shureiqi, D Chen, J J Lee, et al.
Journal of the American Geriatrics Society|July 1, 1994
Causes of death associated with Alzheimer disease: variation by level of cognitive impairment before deathW A Kukull, D E Brenner, C E Speck, et al.
Annals of Surgery|January 1, 1989
A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniquesK I Bland, A K Kimura, D E Brenner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1986
Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trialL B Anthony, M G Krozely, N J Woodward, et al.
Journal of Biological Response Modifiers|October 1, 1990
Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancerP J Creaven, J W Cowens, D E Brenner, et al.
Cancer Treatment Reports|April 1, 1985
Phase II study of spirogermanium in patients with advanced carcinoma of the cervixD E Brenner, N B Rosenshein, M Dillon, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1993
Mutual kinetic interaction between 5-fluorouracil and bromodeoxyuridine or iododeoxyuridine in dogsD E Smith, D E Brenner, C A Knutsen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 16, 2001
Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancerK Krishnan, M T Ruffin, D Normolle, et al.
Cancer Treatment Reports|February 1, 1983
Phase II evaluation of spirogermanium in advanced ovarian carcinomaD E Brenner, H W Jones, N B Rosenshein, et al.
Journal of the National Cancer Institute|August 6, 1997
Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin doseM T Ruffin, K Krishnan, C L Rock, et al.
Pageof 9